24-Hour Dynamic Hormone Profiling Using Microdialysis and Multimodal Data in Adults with Primary Aldosteronism

What this Trial Is About

This research aims to develop a new diagnostic method for primary aldosteronism PA, a common cause of secondary hypertension with higher risk of organ damage if left untreated. The study focuses on evaluating dynamic multisteroid adrenal hormone patterns using 24-hour microdialysis in patients suspected or confirmed to have PA. The goal is to create a sensitive, fast, and easy-to-use diagnostic process by combining hormone profiling with monitoring of blood pressure, tissue glucose, sleep, activity, and food intake. Participants will use the U-Rhythm microdialysis system to collect subcutaneous tissue fluid for 24 hours. This device captures dynamic hormone levels, which are then analyzed using advanced laboratory techniques. Data collection occurs during daily activities and specific diagnostic tests like saline infusion and dexamethasone suppression. Some participants may undergo repeated sampling after treatment to assess changes over time. During the study, participants will have simultaneous monitoring of blood pressure, glucose, sleep patterns, activity levels, and meals alongside hormone sampling. Researchers will measure hormone rhythmicity and its relationship with these factors, including effects of diagnostic tests and cortisol co-secretion. The main outcome is to assess the rhythmic hormone patterns from 2024 to 2028. The study lasts several years, with ongoing data collection to understand hormone fluctuations and improve PA diagnosis.

Dynamic Hormone Profiling and Multimodal Data Capture in Primary Aldosteronism